DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
Transarterial chemoembolization (TACE) based on drug-eluting beads (DEB-TACE) is widely used
for unresectable hepatocellular carcinoma (HCC). However, the long-term survival is still low
after DEB-TACE treatment. In recent years, lenvatinib and anti-PD-1 have exhibited potential
therapeutic effects for advanced HCC. And sorafenib is the standard drug for advanced HCC.
Combining targeted drugs or immunotherapies with DEB-TACE may provide synergistic effects and
facilitate the development of personalized medicine. Therefore, this prospective study aims
to investigate the safety and efficacy of DEB-TACE plus sorafenib or lenvatinib or PD-1
Inhibitor for unresectable HCC.